Answers are grounded in this paper and cite their sources.
A 36-year-old man with HIV infection developed a reaction compatible with an abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. The switch was determined by a more convenient intake. The patient was treated with abacavir twice-daily plus lamivudine and efavirenz for more than 5 years with no side effects. At the time of this change, his CD4 count was 1069 cell/mm(3) and HIV-RNA undetectable. Our case suggests that patients should be carefully monitored after switching, and warned about the potential effects.
No takes yet. Share an insight, caveat, or question.
Gervasoni et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: